10-K: Aethlon Medical Reports Continued Losses Amidst Clinical Progress and Capital Raises; Auditors Express Going Concern Doubt

Aethlon Medical, a clinical-stage medical therapeutic company, reported significant operating losses for fiscal year 2025, with auditors raising substantial doubt about its ability to continue as a going concern, despite progress in its Hemopurifier clinical trials and recent capital raises.

Summary

• Aethlon Medical, Inc. is a medical therapeutic company developing the Hemopurifier (HP), a clinical-stage immunotherapeutic device for cancer, life-threatening viral infections, and organ transplantation.
• The Hemopurifier has received U.S. FDA Breakthrough Device designation for two independent indications: advanced/metastatic cancer unresponsive to standard therapy, and life-threatening viruses without approved therapies.
• The company reported a net loss of approximately $13.388 million for the fiscal year ended March 31, 2025, compared to $12.208 million in fiscal year 2024.
• Operating expenses decreased to $9.341 million in FY2025 from $12.636 million in FY2024, primarily due to reductions in payroll, professional fees, and general and administrative costs, partially offset by increased clinical trial expenses.
• Research and development expenses were approximately $2.212 million in FY2025, down from $2.520 million in FY2024.
• Cash and cash equivalents stood at $5.501 million as of March 31, 2025, a slight increase from $5.441 million at March 31, 2024.
• The company raised aggregate net proceeds of $7.746 million in FY2025 through a public offering in May 2024 ($3.540 million) and a warrant inducement offer in March 2025 ($2.151 million net, from $2.316 million gross proceeds from warrant exercises).
• An Australian Phase 1 safety, feasibility, and dose-finding clinical trial for the Hemopurifier in cancer patients with solid tumors is ongoing, with three participants treated in the first cohort as of June 26, 2025.
• A similar clinical trial is planned for India, with HREC approval obtained and formal approval from India's CDSCO awaited.
• Pre-clinical studies demonstrated 98.5% removal of platelet-derived extracellular vesicles (PD-EVs) by the Hemopurifier in a 4-hour treatment simulation, supporting its potential in various diseases including cancer and Long COVID.
• The company regained compliance with Nasdaq's minimum bid price requirement on June 25, 2025, following a 1-for-8 reverse stock split effective June 6, 2025.
• A previously identified material weakness in internal controls over financial reporting related to segregation of duties and user access controls was remediated as of March 31, 2025.
• The company terminated its U.S. and India-based COVID-19 studies due to low ICU patient volume and shifting priorities, but maintains an open IDE for viral indications.
• The company is awaiting FDA approval for a separate supplement to qualify an additional supplier of a key Hemopurifier component (GNA), which has caused delays.
• The independent auditors issued a going concern qualification for the fiscal year ended March 31, 2025, citing recurring losses and the need for additional financing.
• The company has 9 full-time employees as of June 26, 2025.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including recurring significant losses and a 'going concern' qualification from auditors, indicating high risk of business failure without substantial future funding. While there are positive developments in clinical trials and regulatory compliance (Nasdaq listing, internal control remediation), these are overshadowed by the fundamental financial instability and dependence on future capital raises, which are not guaranteed. The ongoing delays in supplier qualification also add to the negative outlook.

Positives

• The Hemopurifier has received U.S. FDA Breakthrough Device designation for two independent indications: advanced/metastatic cancer and life-threatening viruses, which may expedite development and review.
• Positive pre-clinical study results showed 98.5% removal of platelet-derived extracellular vesicles (PD-EVs) by the Hemopurifier, supporting its potential in oncology and other indications like Long COVID.
• The company successfully raised $7.746 million in net proceeds during FY2025 through a public offering and a warrant inducement offer, providing additional capital.
• Aethlon Medical regained compliance with Nasdaq's minimum bid price requirement on June 25, 2025, maintaining its listing.
• The company has remediated a previously identified material weakness in internal controls over financial reporting as of March 31, 2025, improving financial reporting reliability.
• FDA approval was received to begin manufacturing Hemopurifiers at the company's San Diego facility.
• The company has sufficient inventory of Hemopurifiers to support its ongoing Australian oncology trial and potential future trials in India.

Negatives

• The company has incurred significant losses since inception, with a net loss of $13.388 million in FY2025, and expects to continue incurring losses for the foreseeable future.
• The independent auditors issued a going concern qualification for the fiscal year ended March 31, 2025, indicating substantial doubt about the company's ability to continue operations for the next 12 months without additional funding.
• The company will require significant additional financing to sustain operations and fund future clinical trials and R&D activities, which may dilute existing stockholders' ownership.
• The company has no active revenue-generating government contracts in FY2025 and FY2024, and no current research grants.
• The company is dependent on single suppliers for critical Hemopurifier components, and delays in qualifying new suppliers (e.g., GNA) have occurred and may continue.
• The 1-for-8 reverse stock split, while helping regain Nasdaq compliance, significantly reduced the number of outstanding shares and can be perceived negatively by investors.
• The company has limited experience in identifying and working with large-scale contracts with medical device manufacturers, posing a challenge for future commercialization.
• The company has limited experience in the organ transplant market, a new area of exploration, and faces competition from more established entities.
• The company's stock price has historically been volatile and trading volume unpredictable, making it difficult for investors to sell shares at desired prices.

Risks

• Incurring significant losses and expecting continued losses for the foreseeable future, leading to a going concern qualification by independent auditors.
• Requiring additional financing to sustain operations, achieve business objectives, and satisfy cash obligations, which may dilute existing stockholders.
• Delays, interruptions, or cessation of production by third-party suppliers of important materials, or delays in qualifying new materials, preventing or delaying Hemopurifier manufacturing.
• The Hemopurifier technology potentially becoming obsolete due to new scientific or technological developments by competitors.
• Failure to comply with extensive regulations of U.S. and foreign regulatory agencies, which could delay or prevent product commercialization.
• Inability to maintain compliance with Nasdaq Capital Market listing requirements, potentially leading to delisting and reduced liquidity/value of common stock.
• Difficulty attracting and retaining executive management and directors as a public company with limited financial resources and new medical technologies.
• Strain on resources and potential delays in business objectives due to planned expansion of operations and inability to manage growth.
• High dependence on key personnel, with the loss of whom could harm business and delay long-term objectives.
• Delays in successfully commencing or completing planned clinical trials, jeopardizing regulatory approval and sustainability of operations.
• Failure of products or product malfunctions causing or contributing to death or serious injury, leading to medical device reporting regulations, corrective actions, or enforcement actions.
• Reliance on third-party consultants and vendors for operational and development activities, with their failure to perform adequately causing delays or termination of product development.
• Exposure to product liability and clinical/preclinical liability risks, which could result in substantial financial burden if sued, and potentially inadequate insurance coverage.
• Inability to obtain FDA approval to market a medical device in the United States, or approval being limited or revoked.
• Evolving approval requirements for medical products used to fight bioterrorism and pandemics, which products may not meet.
• Clinical trial results not supporting product candidate claims or leading to the discovery of adverse side effects.
• U.S. legislative or FDA regulatory reforms making it more difficult and costly to obtain regulatory approval or to manufacture/market products.
• Current and future business activities being subject to anti-kickback, fraud and abuse, false claims, and other healthcare laws, exposing the company to significant penalties.
• Stringent and changing U.S. and foreign laws, rules, regulations, and standards related to data privacy and security, leading to potential investigations, fines, or disruptions.
• Information technology systems or data being compromised, resulting in adverse consequences from security breaches.
• Lack of third-party coverage and reimbursement for devices, delaying or limiting their adoption if commercialized.
• Adverse changes in healthcare reform measures and reimbursement policies impacting the ability to market and sell products.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes.
• Uncertainties in the interpretation and application of existing, new, and proposed tax laws and regulations materially affecting tax obligations and effective tax rate.
• Exposure to potential liabilities from the use of hazardous materials, chemicals, and viruses, for which insurance may be inadequate.
• Products being subject to recalls, voluntarily or by governmental authority, impacting reputation, financial results, and future sales.
• Breakthrough Device designation not guaranteeing expedited development or review, or ultimate PMA approval.
• Bylaws designating a specific exclusive forum for certain stockholder actions, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• Reliance upon licenses and patent rights from third parties which are subject to termination or expiration.
• Becoming subject to intellectual property litigation that could be costly, divert management, require damages, or prevent product sales.
• Inadequate protection of intellectual property through patents, trade secrets, and contractual provisions, increasing vulnerability to competitors.
• New technology leading to competitors developing superior products, reducing demand for the company's products.
• Potential inability to obtain U.S. Government contracts to further develop technology.
• U.S. Government agencies having special contracting requirements, including audit rights, which create additional risks.
• Unpredictable trading volume and volatility in common stock price, leading to potential losses for investors.
• Issuance of additional shares of common stock or convertible securities being dilutive to existing stockholders.
• Officers and directors being entitled to indemnification, which could be costly and discourage stockholder rights exercise.
• Bylaws and Nevada law potentially discouraging, delaying, or preventing a change of control or management changes, depressing stock price.
• Substantial costs incurred as a public company and management time devoted to compliance programs.
• Limited research coverage by industry and financial analysts, potentially causing stock price or trading volume to decline if coverage ceases or recommendations are adverse.

Future Outlook

Aethlon Medical expects to continue incurring operating losses for the foreseeable future and will require significant additional financing to sustain its operations, fund planned clinical trials in the United States, India, and Australia, achieve regulatory clearances, and continue research and development activities for the Hemopurifier and other future products. The company plans to access equity markets for additional capital, but there is no assurance of obtaining necessary funding. The full impact of global economic conditions, inflation, and military conflicts on timelines and future access to capital remains uncertain. The company aims to explore new indications for the Hemopurifier based on preclinical findings, including in organ transplantation and Long COVID.

Management Comments

• "We believe that the Hemopurifier may be a substantial advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful extracellular vesicles particles that promote the growth and spread of tumors."
• "We also believe that the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment."
• "We maintain an open IDE for viral indications to preserve optionality for future outbreaks or emergent pathogens."
• "We have sufficient inventory of Hemopurifiers to support our ongoing oncology trial in Australia as well as any near-term expansion of that study or potential trial activity in India."
• "While we have received FDA approval to begin manufacturing at our San Diego facility under our IDE supplement, we are still awaiting FDA approval of a separate supplement to qualify an additional supplier of a key Hemopurifier component. We continue to work with the FDA on this process."
• "We believe the data from this pre-clinical study calls for additional study of the Hemopurifier and look forward to receiving feedback from the Long COVID scientific community at the Keystone Symposium."
• "While the Company has been carrying out certain expense reductions since November 2023; our planned additional expense reductions may not materialize and/or our patient recruitment may occur more rapidly than expected along with the concomitant increases in expenses, therefore there is substantial doubt that our cash on hand will carry the company for 12 months beyond the filing date of the financial statements included in this Annual Report."
• "We do plan to access the equity markets for additional capital, however, there can be no assurance that we will be able to access such additional capital."

Industry Context

The medical device industry, particularly for infectious disease and cancer treatments, is highly competitive and capital-intensive. Aethlon Medical operates in a burgeoning field of exosome research, facing competition from well-funded pharmaceutical and biotechnology organizations, as well as academic institutions. The company's clinical-stage device requires significant data from human studies to establish medical industry support and compete effectively. The industry is also subject to extensive and evolving government regulations, including those related to product development, manufacturing, and commercialization, as well as healthcare cost containment measures and data privacy laws. The company's focus on extracorporeal devices for removing harmful particles from blood places it in a niche that could be impacted by advancements in other treatment modalities or diagnostic technologies.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for benchmarking against global industry standards. It generally states that the industry is 'extremely competitive' and that many competitors have 'greater financial, personnel, operational and research and development resources'.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not involved in any litigation or any pending legal proceedings.

Related Party Transactions

• Separation Agreement with former CEO Charles J. Fisher, Jr. M.D., effective November 27, 2023, providing cash severance equivalent to 12 months of base salary, accelerated vesting of 50% of outstanding unvested equity awards, and COBRA healthcare premium reimbursements for 12 months.
• Separation Agreement with former COO Guy F. Cipriani, effective October 3, 2024, providing cash severance equivalent to 12 months of base salary and COBRA healthcare premium reimbursements for 12 months.
• Separation Agreement with former CSO Lee Arnold, effective July 1, 2024, providing cash severance equivalent to 12 months of base salary and COBRA healthcare premium reimbursements for 12 months.
• Accrued Board fees of $68,250 owed to non-employee directors as of March 31, 2025.
• Accrued vacation to all employees of $165,029 as of March 31, 2025 (including $27,126 paid out to former executives and $13,419 to other employees due to reduction in force).
• Accrued separation expenses of $346,286 as of March 31, 2025, primarily related to cash severance and COBRA payments for former executives.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future equity financings needed to sustain operations. The 1-for-8 reverse stock split reduced the number of shares, potentially impacting per-share metrics. The 'going concern' qualification indicates a high risk of investment loss. However, regaining Nasdaq compliance is positive for liquidity and visibility.
• **Employees**: Experienced a workforce reduction in August 2024. Key personnel are critical, and the company's limited financial resources may make attracting and retaining talent difficult. Executive compensation includes base salary, cash bonuses, and equity awards.
• **Customers/Patients**: Potential beneficiaries of the Hemopurifier for cancer and viral infections, especially with Breakthrough Device designation. Clinical trial progress offers hope for new treatment options. However, delays in regulatory approvals and manufacturing could impact product availability.
• **Suppliers**: The company's dependence on single suppliers for critical components creates risk for both the company and its suppliers if issues arise or relationships are disrupted.
• **Creditors**: The 'going concern' qualification and ongoing losses raise concerns about the company's ability to service indebtedness, potentially impacting creditworthiness.

Next Steps

• Present data from the first cohort of the Australian oncology trial to an independent Data Safety Monitoring Board (DSMB) for recommendation on advancing to the next cohort.
• Advance to the next cohort in the Australian oncology trial, where participants will receive two Hemopurifier treatments during a one-week period, pending DSMB recommendation.
• Obtain formal approval letter from the India Regulatory Agency CDSCO for the planned clinical trial in India.
• Commence the clinical trial at Medanta Medicity Hospital in India following a Site Initiation Visit (SIV) by the company's India CRO, Qualtran.
• Continue working with the FDA to obtain approval for a separate supplement to qualify an additional supplier of a key Hemopurifier component (GNA).
• Further explore potential new indications for the Hemopurifier based on pre-clinical findings, including in organ transplantation and Long COVID.
• Receive feedback from the Long COVID scientific community at the Keystone Symposium regarding pre-clinical study data.
• Continue to pursue additional financing through equity and/or debt markets to sustain operations and fund future clinical trials and R&D activities.
• Monitor the impact of inflation, recent bank failures, and ongoing military conflicts on business timelines and future access to capital.
• Non-employee directors will receive annual RSU grants in April 2025, vesting in four equal installments on June 30, 2025, September 30, 2025, December 31, 2025, and March 31, 2026.

Key Dates

Recommendation

Keywords

Hemopurifier, Extracorporeal Therapy, Oncology, Cancer Treatment, Viral Infections, Ebola, HIV, Hepatitis C, COVID-19, Extracellular Vesicles, Exosomes, Medical Device, Clinical Trials, FDA Breakthrough Device, Biotechnology, Medical Technology, Nasdaq Capital Market, SEC Filing, 10-K, Financial Reporting, Going Concern, Capital Raise, Reverse Stock Split, Corporate Governance, Intellectual Property